IBI THERAPY CARDIAC ABLATION SYSTEM ERS/ 1500T RF GENERATOR
Irvine Biomedical, Inc. · Decision date Jan 14, 2005
What did the FDA approve?
The FDA database entry for P040014 records an original PMA approval dated January 14, 2005, for the IBI Therapy Cardiac Ablation System from Irvine Biomedical, Inc. The approval statement describes the device as indicated for mapping and for use with a compatible RF generator for three specific purposes: interruption of accessory atrioventricular conduction pathways associated with tachycardia, treatment of AV nodal re-entrant tachycardia, and creation of complete AV nodal block in patients with a difficult to control ventricular response to an atrial arrhythmia.
The entry lists no supplement type or supplement reason, so no changed item or post-approval modification is described. The product code is LPB and the specialty is cardiovascular. The statement reports the device's stated purpose; it does not by itself provide independent evidence of safety or clinical effectiveness. No information is provided about clinical data, trial results, or comparative performance.
FDA approval order statement
APPROVAL FOR THE IBI THERAPY CARDIAC ABLATION SYSTEM. THE DEVICE IS INDICATED FOR MAPPING AND FOR USE WITH A COMPATIBLE RF GENERATOR FOR: INTERRUPTION OF ACCESSORY ATRIOVENTRICULAR (AV) CONDUCTION PATHWAYS ASSOCIATED WITH TACHYCARDIA; THE TREATMENT OF AV NODAL RE-ENTRANT TACHYCARDIA (AVNRT); OR CREATION OF COMPLETE AV NODAL BLOCK IN PATIENTS WITH A DIFFICULT TO CONTROL VENTRICULAR RESPONSE TO AN ATRIAL ARRHYTHMIA.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 14, 2005
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P040014
- Regulatory pathway
- Premarket approval application
- Applicant
- Irvine Biomedical, Inc.
- Product code
- LPB
- Decision code
- APPR
- Decision date
- Jan 14, 2005
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cardiac ablation percutaneous catheter.
- Applicant
- Irvine Biomedical, Inc.
- Product code
- LPB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P040014 received
Application receipt date recorded by FDA.
P040014 · FDA decision
APPR
P040014/S052 · Related supplement
Therapy (including Bi-Directional and 4mm Thermistor) Ablation Catheter
Timeline entries are records held by MedtechLedger for P040014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Irvine Biomedical, Inc. | PMA supplement | Sep 3, 2026 | FDA |
Explore the linked device profile
Other records with product code LPB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
| Biosense Webster, Inc. | PMA approval | Aug 11, 2006 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Irvine Biomedical, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2375 Morse Ave., Irvine, CA, 92614
Sources and methodology
- Original FDA record: P040014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records